Premium
Antiretroviral therapy in HIV‐1‐infected individuals with CD4 count below 100 cells/mm 3 results in differential recovery of monocyte activation
Author(s) -
Patro Sean C.,
Azzoni Livio,
Joseph Jocelin,
Fair Matthew G.,
SierraMadero Juan G.,
Rassool Mohammed S.,
Sanne Ian,
Montaner Luis J.
Publication year - 2016
Publication title -
journal of leukocyte biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.819
H-Index - 191
eISSN - 1938-3673
pISSN - 0741-5400
DOI - 10.1189/jlb.5ab0915-406r
Subject(s) - maraviroc , cd163 , cd14 , monocyte , cd16 , cd38 , immunology , macrophage , biology , cd8 , t cell , viral load , cd68 , immune system , cd3 , virus , cd34 , human immunodeficiency virus (hiv) , biochemistry , immunohistochemistry , stem cell , in vitro , genetics
In advanced HIV‐1 disease, 24 weeks of ART‐mediated recovery results in reversal of activated cell‐specific monocyte subsets, with minimal recovery of soluble makers of tissue‐associated myeloid activation.